Anixa Biosciences annual debt-to-equity ratio
2015
2020
2021
2022
2023
2024
2025
Anixa Biosciences Debt-to-Equity Ratio Growth & History (ANIX)
Anixa Biosciences's debt-to-equity ratio was 0.01 for fiscal 2025.
View full Anixa Biosciences company overviewAnixa Biosciences annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-10-31 | 0.01 | 0.00 | +15.98% |
| 2024 | 2024-10-31 | 0.01 | 0.00 | +61.34% |
| 2023 | 2023-10-31 | 0.01 | −0.00 | −5.49% |
| 2022 | 2022-10-31 | 0.01 | 0.00 | +3.91% |
| 2021 | 2021-10-31 | 0.01 | 0.00 | +16.22% |
| 2020 | 2020-10-31 | 0.01 | — | — |
| 2015 | 2015-10-31 | 0.07 | — | — |
Anixa Biosciences quarterly debt-to-equity ratio
Q3.14
Q4.15
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-04-30 | 0.01 | −0.00 | −7.58% |
| Q1 2026 | 2026-01-31 | 0.01 | −0.00 | −0.64% |
| Q4 2025 | 2025-10-31 | 0.01 | 0.00 | +15.98% |
| Q3 2025 | 2025-07-31 | 0.01 | 0.00 | +17.91% |
| Q2 2025 | 2025-04-30 | 0.01 | 0.01 | +118.06% |
| Q1 2025 | 2025-01-31 | 0.01 | 0.01 | +95.68% |
| Q4 2024 | 2024-10-31 | 0.01 | 0.00 | +61.34% |
| Q3 2024 | 2024-07-31 | 0.01 | 0.00 | +48.56% |
| Q2 2024 | 2024-04-30 | 0.01 | −0.00 | −14.59% |
| Q1 2024 | 2024-01-31 | 0.01 | −0.00 | −12.45% |
| Q4 2023 | 2023-10-31 | 0.01 | −0.00 | −5.49% |
| Q3 2023 | 2023-07-31 | 0.01 | 0.00 | +0.56% |
| Q2 2023 | 2023-04-30 | 0.01 | −0.00 | −1.42% |
| Q1 2023 | 2023-01-31 | 0.01 | 0.01 | +102066.41% |
| Q4 2022 | 2022-10-31 | 0.01 | 0.00 | +3.91% |
| Q3 2022 | 2022-07-31 | 0.01 | 0.01 | +2414.71% |
| Q2 2022 | 2022-04-30 | 0.01 | 0.01 | +985.24% |
| Q1 2022 | 2022-01-31 | 0.00 | −0.00 | −99.75% |
| Q4 2021 | 2021-10-31 | 0.01 | 0.00 | +16.22% |
| Q3 2021 | 2021-07-31 | 0.00 | −0.01 | −96.37% |
| Q2 2021 | 2021-04-30 | 0.00 | −0.01 | −95.53% |
| Q1 2021 | 2021-01-31 | 0.00 | −0.01 | −82.65% |
| Q4 2020 | 2020-10-31 | 0.01 | — | — |
| Q3 2020 | 2020-07-31 | 0.01 | — | — |
| Q2 2020 | 2020-04-30 | 0.02 | — | — |
| Q1 2020 | 2020-01-31 | 0.02 | — | — |
| Q4 2015 | 2015-10-31 | 0.07 | — | — |
| Q3 2014 | 2014-07-31 | 11.73 | — | — |
Anixa Biosciences debt-to-equity ratio trends
Over the last five fiscal years, Anixa Biosciences's debt-to-equity ratio increased from 0.01 to 0.01, a change of 0.01. The latest reported quarter, Q2 2026, shows 0.01.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anixa Biosciences source filings ↗